The Oral Solid Dosage Pharmaceutical Formulation Market is projected to achieve USD 8,95,636.0 million by 2034, up from its estimated USD 6,29,582.6 million in 2024.
Market dynamics of oral solid dosage pharmaceutical formulations are primarily influenced by factors such as the expanding elderly population that needs long-term pharmaceutical treatment, the progress of drug formulation technologies, and the growing demand for oral pharmaceuticals.
Between 2024 and 2034, the oral solid dosage pharmaceutical formulation market is anticipated to advance at a CAGR of 3.7%. Drug administration technologies have seen significant innovation in the oral solid dosage pharmaceutical formulation industry, increasing patient compliance and efficacy.
The market opportunity of oral solid dosage pharmaceutical formulation to develop and change in response to the constantly changing healthcare environment.
| Attributes | Details |
|---|---|
| Market Value for 2024 | USD 6,29,582.6 million |
| Market Value for 2034 | USD 8,95,636.0 million |
| Market CAGR from 2024 to 2034 | 3.7% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Continuous developments in pharmaceutical production technology, such as novel equipment and methods, aid in the creation of oral solid dosage formulations that are more economical and efficient.
These developments accelerate oral solid dosage pharma formulation market expansion by improving the pharmaceutical products' quality, safety, and repeatability.
Market dynamics are influenced by patients' preference for oral drugs, which are motivated by familiarity with and convenience in usage. Consumers are accepting oral solid dosage forms, which fosters oral solid dosage pharmaceutical formulation industry expansion.
The aging of the global population is increasing the prevalence of chronic illnesses. The pharmaceutical industry is expanding due to a growing demand for oral solid dosage forms that address chronic diseases.
| Attributes | Details |
|---|---|
| Market Value for 2019 | USD 6,29,582.6 million |
| Market Value for 2023 | USD 6,29,582.6 million |
| Market CAGR from 2019 to 2023 | 2.8% |
Complex facilities, sophisticated machinery, and knowledgeable workers are required to produce oral solid dosage forms. Smaller pharmaceutical companies are barriers to entry due to high initial capital investment and continuous operating costs associated with production facilities.
Government policies that support generic replacement and cost-cutting efforts in healthcare systems negatively impact the oral solid dose pharmaceutical formulation market. Policies that require or reward generic replacement pressure prices and diminish the market share of branded goods.
Principal Consultant
The segmented oral solid dosage pharmaceutical formulation market analysis is included in the following subsection. Based on comprehensive research, the immediate release sector is controlling the drug release mechanism category, and the tablets segment dominates the dosage form category.
| Segment | Immediate Release |
|---|---|
| Share (2024) | 43.30% |
Immediate release drugs are more convenient and increase patient compliance, which boosts sales of oral solid dosage pharmaceutical formulations. Evident in prescribers' general preference for first-line therapies is the dominance of immediate release segment.
Given their applicability across a range of therapeutic domains, the immediate release segment continues to enjoy substantial demand for oral solid dosage pharmaceutical formulation.
Easy administration and flexible dosage schedules are two factors supporting immediate release formulations' ongoing prominence in the oral solid dose pharmaceutical formulation market.
| Segment | Tablets |
|---|---|
| Share (2024) | 48.90% |
Due to their affordability, patient familiarity, and manufacturing convenience, tablets account for the majority of sales of oral solid dosage pharmaceutical formulation. Even with many alternatives, the oral solid dosage pharmaceutical formulation industry favors tablets as a reliable, effective, and commonly recognized dosage form.
Then, follow capsules, which are more adaptable and have better drug stability, making them suitable for various formulations. Powders and granules, particularly in formulations for children and the elderly, are prevalent for individualized dosing.
Pastilles and lozenges target specific therapeutic areas and are prized for their targeted distribution and ability to increase patient compliance. Gummies are a growing trend that draws consumers looking for new and tasty substitutes, propelling the nutraceutical industry's growth.
The oral solid dosage pharmaceutical formulation market can be observed in the subsequent tables, which focus on the leading regions in North America, Europe, and Asia Pacific.
A comprehensive evaluation demonstrates that Asia Pacific has enormous market opportunities for oral solid dosage pharmaceutical formulation.
Oral Solid Dosage Pharma Formulation Opportunities in Asia Pacific
| Countries | CAGR (2024 to 2034) |
|---|---|
| China | 7.2% |
| South Korea | 6.8% |
| Japan | 3.3% |
Given its size and changing regulatory environment, China offers many opportunities for oral solid dosage pharmaceutical formulations. The increasing emphasis on healthcare accessibility and the rising demand for oral solid dosage forms promote China's pharmaceutical industry's rapid expansion.
Advancements in manufacturing and new technology are fostering China's oral solid dosage pharma formulation market expansion.
The market is expanding owing to the South Korean government's encouraging policies and investments in research and development facilities. South Korea is a desirable center for the regional manufacture and export of oral solid dosage formulations due to its advantageous location and robust intellectual property protection.
Technology and manufacturing process developments are continually raising the productivity and competitiveness of the South Korean oral solid dosage pharmaceutical formulation industry.
Innovation in oral solid dosage pharmaceutical formulations is in high demand in Japan due to the country's aging population and rising rates of chronic diseases. Oral solid dose forms are developed under the influence of Japan's pharmaceutical industry, distinguished by an emphasis on tailored medicines and precision medicine.
Japan's oral solid dose pharmaceutical formulation market experiences innovation caused by ongoing investment in research and development and advances in manufacturing technology.
Market Growth Analysis of Oral Solid Dosage Pharma Formulation in Europe
| Countries | CAGR (2024 to 2034) |
|---|---|
| France | 4.6% |
| Italy | 3.8% |
| Spain | 2.7% |
| United Kingdom | 2.1% |
| Germany | 1.6% |
Strict laws controlling oral solid dose pharmaceuticals result from the French market's emphasis on quality and safety standards. Specialized oral solid dose formulations suited to geriatric healthcare needs are in high demand due to France's aging population.
The French government's healthcare policies aim to ensure that oral solid dosage pharmaceuticals are widely available to the general public.
Naturally occurring oral solid dose formulations are strongly affected by the rich history of herbal therapy that Italy's pharmaceutical industry has enjoyed. Italians place a high priority on preventative healthcare, which ignites the oral solid dosage pharma formulation market that addresses illnesses related to lifestyle, like metabolic disorders.
Producers of oral solid dosage pharmaceutical formulation prioritize cost-effective oral solid dosage formulations without sacrificing quality in the Spanish market, where pricing is an integral factor. Spain's regulatory framework supports environmentally sustainable approaches in the manufacturing of oral solid doses.
Collaborative efforts between Spanish pharmaceutical companies and research institutions facilitate the creation of innovative oral solid dose formulations for rare illnesses.
The development of customized oral solid dosage formulations based on genetic profiles is stimulated by the United Kingdom pharmaceutical market's emphasis on personalized medicine. To meet healthcare demands at a reasonable cost, the National Health Service (NHS) in the United Kingdom is a major influence on developments in oral solid dose formulation.
Sustained-release formulations and other innovative oral solid dose formulation technologies are made possible by Germany's substantial expenditure on research and development.
The German healthcare system has influenced the creation of user-friendly oral solid dosage formulations with clear dosing instructions, which promotes patient education and self-management.
Market Dynamics of Oral Solid Dosage Pharmaceutical Formulation in North America
| Countries | CAGR (2024 to 2034) |
|---|---|
| Canada | 2.8% |
| United States | 1.7% |
In the United States, advances in oral solid dosage pharmaceutical formulations are stimulated by the rising need for generic medications and the growing emphasis on individualized therapy. The United States' oral solid dosage pharmaceutical production landscape is changing due to the emergence of contract manufacturing organizations, or CMOs.
The Canada oral solid dosage pharmaceutical formulations market witnessed an increased demand for user-friendly formulations due to consumers' growing preference for over-the-counter pharmaceuticals.
In Canada, particularly in rural areas, the rise of e-pharmacies and telemedicine is opening up fresh pathways for oral solid dosage pharmaceutical delivery and accessibility.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
With their knowledge and inventiveness, key oral solid dosage pharmaceutical formulation vendors rule the market in the fiercely competitive field. These oral solid dosage pharmaceutical formulation producers advance the development of pharmaceutical formulations by contributing various strengths.
Pfizer, Novartis, and AstraZeneca are renowned for their broad product lines and dedication to innovation.
Merck, Eli Lilly, and AbbVie are proficient in particular therapeutic domains, augmenting the market's products. Johnson & Johnson and Teva Pharmaceuticals are important contributors to the accessibility and affordability of oral solid dosage pharmaceutical formulations.
In this highly competitive environment, oral solid dosage pharmaceutical formulation providers constantly strive to bring novel formulations, better drug delivery systems, and improve patient outcomes through ongoing research and development activities.
Supply chain management, quality control, and regulatory compliance are still essential for preserving the market competitiveness of oral solid dosage pharmaceutical formulation.
The dynamic competition in the market compels oral solid dosage pharmaceutical formulation manufacturers to innovate, provide high-quality products and services, and prioritize accessibility in response to changing healthcare requirements.
Latest Advancements
| Company | Details |
|---|---|
| Catalent | In February 2023, Catalent paid USD 475 million to purchase Metrics Contract Services to increase its production capacity for oral solid dose and high-potency pharmaceuticals. |
| Pfizer | In March 2023, Pfizer introduced Lyrica (pregabalin) in a new extended-release tablet format for the treatment of neuropathic pain. |
| Eli Lilly & Company | Eli Lilly & Company announced the release of Trulicity, a novel bilayer tablet formulation intended to treat type 2 diabetes, in April 2023. |
| Farxiga | The new once-daily oral tablet version of Farxiga for the treatment of type 2 diabetes and heart failure with maintained ejection fraction was announced by AstraZeneca plc in May 2023. |
| Novartis AG | Novartis AG announced in June 2023 the launch of its new extended-release Vytorin tablet formulation for treating high cholesterol. |
The oral solid dosage pharmaceutical formulation industry to possess a valuation USD 6,29,582.6 million in 2024.
The oral solid dosage pharmaceutical formulation industry is estimated to hit a worth of USD 8,95,636.0 million by 2034.
Through 2034, the oral solid dosage pharmaceutical formulation industry is anticipated to spur at a sluggish CAGR of 3.7%.
From 2019 to 2023, the oral solid dosage pharmaceutical formulation industry registered a 2.8% HCAGR.
The immediate release sector is scheduled to garner a share of 43.3% in 2024.
A 48.9% market share is expected for the tablets sector in 2024.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Dosage Form 5.1. Tablets 5.2. Capsules 5.3. Powders & Granules 5.4. Lozenges & Pastilles 5.5. Gummies 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Drug Release Mechanism 6.1. Immediate Release 6.2. Delayed Release 6.3. Controlled Release 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel 7.1. Hospital Pharmacies 7.2. Retail Pharmacies 7.3. Drug Stores 7.4. Online Pharmacies 7.5. Hypermarkets/Supermarkets 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region 8.1. North America 8.2. Latin America 8.3. Western Europe 8.4. Eastern Europe 8.5. South Asia and Pacific 8.6. East Asia 8.7. Middle East and Africa 9. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 10. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 11. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 12. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 13. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 14. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 15. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 16. Key Countries Market Analysis 17. Market Structure Analysis 18. Competition Analysis 18.1. AstraZeneca Plc. 18.2. Bristol-Myers Squibb Company 18.3. Eli Lilly and Company 18.4. Gilead Sciences 18.5. Merck & Co. Inc 18.6. Novartis AG 18.7. Pfizer Inc. 18.8. AbbVie Inc. 18.9. Boehringer Ingelheim GmbH 18.10. F. Hoffman-La-Roche Ltd. 18.11. Johnson & Johnson 18.12. Biogen Inc. 19. Assumptions & Acronyms Used 20. Research Methodology
Healthcare
July 2023
REP-GB-17655
250 pages
Explore Healthcare Insights
View Reports
Oral Solid Dosage Pharmaceutical Formulation Market
